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This commentary refers to ‘Appropriate cohort selection
and its impact on a meta-analysis evaluating the efficacy of
direct oral anticoagulants post-percutaneous coronary
intervention’, by P. Agasthi et al., 2020;41:1700.
We thank Dr Agasthi and colleagues for their interest in our meta-
analysis1,2 and for drawing our attention to the finding that double
antithrombotic therapy with direct oral anticoagulants (DOAC-
DAT) is associated to an increased risk of stent thrombosis (ST) as
compared to triple antithrombotic therapy with vitamin K antago-
nists. Their argumentations are two-fold:
(1) We included all patients participating in the AUGUSTUS study irre-
spective of whether they received percutaneous coronary interven-
tion (PCI) at index event.
(2) A signal suggesting higher ST risk was observed with dabigatran 110
mg but less so with dabigatran 150 mg within the RE-DUAL PCI
study.
The rationale for including all study participants and not just
those who received PCI shortly before study inclusion arises from
the need to respect the randomization process, while avoiding ar-
bitrary selection of a post-randomization subgroup for which ran-
domization was not stratified for. It is noteworthy emphasizing
that even patients who did not receive PCI or stent implantation
at the time of qualifying event were exposed to the risk of ST be-
cause of stent-assisted procedure performed in the past. Indeed,
two of the overall 32 definite/probable ST cases observed during
the study occurred in patients allocated to DAT who received
stent implantation prior to but not at the time of qualifying event.
Restricting the analysis to patients within the AUGUSTUS trial
who had stent implantation at the time of qualifying event yields
entirely consistent results with respect to the pooled relative risk
increase for the endpoint definite/probable ST with DOAC-DAT,
with 80% of the events occurring within 30days from randomiza-
tion as recently published.3
An arbitrary selection of patients who received only one of the
two tested dabigatran doses within the RE-DUAL PCI trial would
even be more questionable. All patients in the USA and non-elder-
ly patients in other countries were randomly assigned to the 110-
mg DAT group, the 150-mg DAT group, or the TAT group in a
1:1:1 ratio. Elderly patients outside the USA were randomly
assigned to the 110-mg DAT group or the TAT group in a 1:1
ratio; they were not eligible to be assigned to the 150-mg DAT
group, in accordance with the recommendations of the dabigatran
label in those countries. Based on this asymmetric randomization
process and limited statistical power, the statistical analysis plan of
the trial pre-specified that both dabigatran doses had to be ana-
lysed together and contrasted with TAT. As such, the observation
that numerical higher rates of ST occurred mainly in patients taking
the low but not the high dabigatran regimen can be subject to a
considerable play of chance. Finally, a numerical excess of ST
occurred in the DOAC-DAT arm of the AUGUSTUS trial despite
the use of apixaban at full and approved regimen for stroke pre-
vention (i.e. 5mg b.i.d.). Hence, whether the use of a full non-vita-
min K antagonist oral anticoagulant regimen helps mitigate the ST
risk observed consistently across all DOAC-DAT trials remains
currently speculative.
We therefore stand with our prior conclusion and believe that the
higher risk of ST is real as it comes consistently across all included
studies without heterogeneity.
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Vasospastic angina following immune checkpoint blockade
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A 57-year-old man had renal cell carcinoma with lung and bone
metastases and had undergone 2 cycles of anticancer treatment
with an immune checkpoint inhibitor, nivolumab (3mg/kg, every
2weeks). Two weeks after the last administration of nivolumab, he
was admitted to our hospital due to several episodes of rest angina,
especially at night and in the early morning. Resting chest pain, which
lasted for 5–20min, appeared 3 days after the first nivolumab admin-
istration and gradually worsened. He had no history of heart disease.
Previous management of his renal cell carcinoma involved chemo-
therapy with sunitinib and axitinib. He had never received radiation
therapy to his chest. After admission, he had spontaneous episodes
of rest angina with transient ischaemic electrocardiographic (ECG)
changes that promptly resolved with nitrate. He underwent coro-
nary angiography 3 days after admission. Immediately after entering
the catheterization laboratory, he complained of chest pain, and his
ECG showed ST depression in multiple leads (Panel A). Coronary
angiography revealed multiple spasms throughout the coronary bed
(Panel B), which was resolved after intracoronary nitroglycerine
administration (Panel C). He was diagnosed with vasospastic angina,
and the symptoms disappeared gradually with the up-titration of a
calcium channel blocker and a nitrate. He was able to continue nivo-
lumab treatment without recurring chest pain under coronary vasodilator medication.
In summary, this is a rare case of vasospastic angina following immune checkpoint blockade. Cardiologists and oncologists should be vigi-
lant for vasospasm as a possible immune-related adverse event.
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
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